Skip to main content

Table 2 Plasma phospholipids fatty acid levels after EPA + DHA and placebo supplementation in 12 men with type 2 diabetes

From: Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes

  Placebo EPA + DHA Difference P
  Fatty acid levels (%)
LA 19.9 (3.6) 19.3 (2.9) −0.6 0.09
ALA 0.21 (0.09) 0.19 (0.11) −0.02 0.85
DGLA 3.82 (1.57) 2.87 (0.65) −0.95 0.001
AA 9.40 (2.05) 7.97 (1.37) −1.43 0.0005
EPA 1.00 (0.93) 3.53 (1.65) 2.53 0.0005
DPA 1.03 (0.34) 1.25 (0.26) 0.22 0.0005
DHA 2.96 (1.15) 4.43 (1.26) 1.47 0.0005
  1. Data are expressed as median and interquartile range in parentheses. P values were calculated using Wilcoxon matched-pairs signed-rank tests. Abbreviations: AA, arachidonic acid; ALA, alpha-linolenic acid; DGLA, dihomo-γ-linoleic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; PUFA, polyunsaturated fatty acids.